One of the prominent pharmacological features of drugs acting at the brain cannabinoid receptor (CB 1 ) is the induction of alterations in motor behavior. Catalepsy, immobility, ataxia, or the impairment of complex behavioral acts are observed after acute administration of either natural and synthetic cannabinoid receptor agonists or the endogenous CB 1 ligand anandamide. The dense presence of CB 1 receptors in the cerebellum and in the basal ganglia, especially at the outflow nuclei (substantia nigra and the internal segment of the globus pallidus), supports the existence of an endogenous cannabinoid system regulating motor activity. In the basal ganglia, the functionality of the anandamide-CB 1 system is poorly understood. Dual effects are often observed after the administration of CB 1 ligands in animal models of pharmacological manipulation of basal ganglia transmitter systems, indicating that the activity of the anandamide-CB 1 system depends on the ongoing activation of the different elements of the basal ganglia. This finding is in agreement with the proposed activitydependent release of anandamide from a plasmalemma precursor. Additionally, a potential statedependent bidirectional coupling of the CB 1 receptor to the adenylate cyclase transduction system has also been described. From this perspective, the endogenous cannabinoid system can be proposed as a local regulator of neurotransmission processes within the basal ganglia. This system may serve as a counterregulatory homeostatic mechanism preserving the functional role of basal ganglia circuits in coding the serial order of events that constitute movement. 1998 Academic Press
INTRODUCTION
Early studies in the first half of the 20th century described the characteristic profile of motor effects produced by acute exposure to Cannabis sativa extracts (hashish). They included hypokinesia, catalepsy, and static ataxia (1, 2). The isolation and chemical synthesis of ⌬ 9 -tetrahydrocannabinol (THC), the main psychoactive component of Cannabis (3), and the subsequent synthesis of potent stereoisomers (4, 5), such as (Ϫ)-⌬ 8 -THC-dimethylheptyl, allowed to fully describe the motor effects of systemically administered cannabinoids. Pharmacological models of drug evaluation included thereon the disruption of motor behavior as one of the predictors of cannabinoid-like activity, together with analgesia and hypothermia (2, 6). The clear effects of cannabinoids on motor behavior led during the 1980s to clinical evaluations on the effects of cannabis consumption in the evolution of motor disorders symptoms such as spasticity (7) and prompted the first clinical studies on the application of cannabinoidrelated compounds on motor diseases, including tremor and dystonias (8, 9 and Consroe, this issue). However, most of these studies were based in speculative hypothesis: there was a gap in our understanding of the cannabinoid actions in the regulation of motor behavior since the neural targets of these compounds re-
